Prime Medicine ($PRME) Stock Forecast: Down 5.1% Today

What is Prime Medicine?

Prime Medicine, Inc. (NYSE: PRME) is a clinical-stage gene-editing company specializing in single-dose treatments for diseases using prime editing technology. Today, the stock experienced a strong bearish movement.

Why is Prime Medicine going down?

PRME stock is down 5.1% on Feb 10, 2026 20:50

• Despite receiving a "Moderate Buy" consensus rating from seven brokerages, PRME's stock saw a significant decline.
• The average 12-month price target of $7.21 indicates optimism in the company's future performance, but the market reacted negatively.
• Institutional investors holding a substantial portion of the stock may have contributed to the heightened selling pressure, leading to the bearish movement.
• The disconnect between the positive analyst recommendations and the actual market performance suggests that external factors or unexpected news may have influenced the stock's decline.

PRME Price Chart

PRME Technical Analysis

PRME News

Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Brokerages

Seven brokerages have issued a "Moderate Buy" consensus rating for Prime Medicine, Inc. (NYSE:PRME), with an average 12-month price target of $7.21. The clinical-stage gene-editing company focuses on developing single-dose treatments for various diseases using its proprietary prime editing technology. Shares recently opened at $3.57 and saw a 10.2% increase, with institutional investors holding a significant portion of the stock.

https://www.marketbeat.com/instant-alerts/prime-medicine-inc-nyseprme-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-02-09/

Trending Today

Monero ($XMR) Crypto Forecast: Up 6.1% Today

Prime Medicine ($PRME) Stock Forecast: Down 5.1% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.2% Today

Unity Software ($U) Stock Forecast: Up 5.1% Today

Broadridge Financial Solutions Inc.Common Stock ($BR) Stock Forecast: Down 5.0% Today

Marriott International ($MAR) Stock Forecast: Up 8.8% Today

WESCO International, Inc. ($WCC) Stock Forecast: Down 6.8% Today

Masco Corporation ($MAS) Stock Forecast: Up 9.4% Today

Quest Diagnostics Incorporated ($DGX) Stock Forecast: Up 7.3% Today

IQVIA Holdings Inc. ($IQV) Stock Forecast: Down 5.2% Today

Prime Medicine Price History

06.00.2026 - PRME Stock was up 7.6%

• PRME observed a rise in its stock price after receiving a favorable assessment from an investment firm, which set an Outperform rating and a $6 price target. The company's innovative gene editing treatments for liver and lung diseases were highlighted as particularly noteworthy.
• The release of successful Phase 1/2 clinical trial results for PM359 further solidified investor belief in PRME. These results were published, showcasing the effectiveness and safety of Prime Editing technology for chronic granulomatous diseases in a well-known medical journal.
• The positive outcomes from the clinical studies, such as swift neutrophil engraftment and lasting patient improvements, likely influenced the favorable market reception towards PRME.
• In essence, the combination of encouraging analyst feedback, groundbreaking clinical trial data, and the potential of Prime Medicine's gene editing technology were key factors behind the surge in PRME stock value today.

15.11.2025 - PRME Stock was down 5.4%

• The bearish movement in PRME's stock today can be attributed to the fact that despite a recent 28% rise in stock value, the company's shares are still trading below the 50-day simple moving average. This indicates a potential lack of sustained momentum in the stock price.
• The negative sentiment from Wall Street analysts, who have issued "sell" ratings due to weak fundamentals such as an EPS miss and negative net margin, could have contributed to the downward pressure on PRME's stock.
• Despite the positive news of successful clinical trial results for PM359, a gene therapy for Chronic Granulomatous Disease, the market may be reacting cautiously due to the inherent regulatory scrutiny and market volatility associated with the gene therapy sector.
• The significant increase in market capitalization following insider stock buying might have initially boosted investor confidence, but ongoing concerns about the company's financial health and overall market conditions could be tempering the stock's performance.

04.01.2026 - PRME Stock was down 5.7%

• Despite a substantial US$110 million decrease in market cap for Prime Medicine, Inc. (PRME) last week, institutional investors show confidence in the company's strong long-term returns.
• Strong one-year gains of 44% potentially offset the recent market cap decline, displaying resilience amidst short-term market fluctuations.
• Institutional ownership stands at 44%, with significant insider holdings indicating optimism about the company's future, potentially explaining the lack of concern among investors regarding the recent market downturn.
• The stock price appears sensitive to institutional trading activities, underscoring the influence of their decisions on market movements and emphasizing the need to monitor institutional sentiment for insights into PRME's future performance.

10.01.2026 - PRME Stock was down 5.1%

• Despite receiving a "Moderate Buy" consensus rating from seven brokerages, PRME's stock saw a significant decline.
• The average 12-month price target of $7.21 indicates optimism in the company's future performance, but the market reacted negatively.
• Institutional investors holding a substantial portion of the stock may have contributed to the heightened selling pressure, leading to the bearish movement.
• The disconnect between the positive analyst recommendations and the actual market performance suggests that external factors or unexpected news may have influenced the stock's decline.

22.00.2026 - PRME Stock was up 7.0%

• A significant increase in stake by Sumitomo Mitsui Trust Group Inc. by 127.7% in the third quarter reflects strong confidence in PRME's future prospects.
• The high institutional ownership of about 70.37% suggests strong support from large investors, potentially benefiting the stock price.
• Analysts' "Moderate Buy" rating and the average price target of $7.21 may have contributed to the positive sentiment, signaling promising growth potential for PRME.

14.00.2026 - PRME Stock was up 5.1%

• PRME stock experienced a bullish movement today following the company's announcement of an updated corporate strategy for its Prime Editing platform, which included detailed timelines for clinical and regulatory milestones in liver, lung, and oncology programs.
• The positive market response can be attributed to Prime Medicine's progress in advancing its gene-editing technology, with plans to file regulatory applications and initiate Phase 1 trials for liver-focused candidates in 2026, as well as the anticipation of significant milestones from a partnership.
• Investors likely reacted favorably to the company's projected expansion of its pipeline through organic growth and partnerships, showcasing the broad therapeutic potential of Prime Medicine's platform in addressing a wide range of genetic diseases.
• Overall, the bullish movement in PRME stock reflects investor confidence in the company's innovative approach to gene editing and the promising developments in its Prime Editing technology, positioning Prime Medicine as a key player in the biotech industry.

11.11.2025 - PRME Stock was up 5.3%

• PRME's market capitalization increased by US$161 million, with a 28% rise in stock value, driven by a year of insider stock buying. The CEO and other insiders' significant purchases at lower prices reflect confidence in the company's undervaluation and future prospects.
• The positive stock movement was also influenced by the successful Phase 1/2 clinical trial results for PM359, a gene therapy for Chronic Granulomatous Disease, published in prestigious journals revealing the company's scientific breakthroughs and potential for long-term growth.
• The high insider ownership of 15% and the significant R&D investment by Prime Medicine indicate a strong foundation for future success, despite challenges in the gene therapy sector such as regulatory scrutiny and market volatility.
• Overall, the combination of insider confidence through stock purchases, successful clinical trial results, and positive publications contributed to PRME's bullish market movement, highlighting investor optimism in the company's innovative approach to gene therapy.

15.00.2026 - PRME Stock was down 6.4%

• Recently, Prime Medicine (PRME) witnessed a significant decline in its stock value, influenced by several factors:
• The company disclosed a quarterly EPS loss that exceeded expectations, coupled with lower revenue figures, indicating unfavorable profit margins, which potentially raised concerns among stakeholders regarding its financial standing.
• Analyst assessments were mixed, with several issuing "sell" recommendations, potentially contributing to the stock's downward trajectory.
• Despite unveiling an updated corporate strategy for its Prime Editing platform and sharing detailed timelines for its clinical and regulatory initiatives, market response suggests a sense of investor skepticism regarding the company's capacity to meet its targets.
• The projected submission of regulatory applications and commencement of Phase 1 trials for liver-focused candidates in 2026 may not have been adequate to counterbalance the negative market sentiment stemming from Prime Medicine's recent financial outcomes.

27.00.2026 - PRME Stock was up 5.1%

• An analyst reaffirmed a "buy" rating for Prime Medicine (PRME.US) and kept a target price of $5.
• The positive analyst rating likely played a role in the stock's upward movement.
• Investor optimism about Prime Medicine's gene editing therapies and the analyst's target price could have influenced the stock's performance.
• The news of the analyst's rating may have increased investor confidence in the company's future, leading to heightened buying activity and an increase in the stock price.

24.11.2025 - PRME Stock was down 5.0%

• Despite falling short of projected quarterly EPS and showing minimal revenue, an upgrade to a "strong-buy" rating by Lifesci Capital could have led to initial investor optimism.
• Nevertheless, the company's notable negative margins and return on equity, combined with other entities issuing "sell" recommendations, may have fueled increased selling activity and the downward movement in the stock price.
• Speculation arose among investors due to the CEO hinting at a shift in focus towards larger opportunities in different diseases, potentially contributing to the uncertainty surrounding the stock and its decline.
• The fluctuating opinions of analysts, the company's strategic adjustments, and its financial performance likely played a crucial role in the bearish trend witnessed in PRME's market performance for the day.

03.01.2026 - PRME Stock was down 8.7%

• Despite Prime Medicine, Inc. experiencing a US$110 million decrease in market cap last week, institutional investors have still benefited from 36% gains over the past year.
• The high sensitivity of the stock price to institutional trading actions, with institutions holding a substantial 44% ownership in the company, likely contributed to the bearish movement.
• The concentration of ownership among the top 8 shareholders, who collectively own more than half of the company's shares, could have influenced the market sentiment and led to the downward trend in PRME stock.
• The long-term gains for institutional investors juxtaposed with the recent market cap decrease may indicate a temporary setback rather than a fundamental issue with the company, potentially offering a buying opportunity for savvy investors looking at the bigger picture.

08.00.2026 - PRME Stock was down 5.7%

• The bearish movement in PRME stock could be due to investors having high expectations from the upcoming presentation at the J.P. Morgan Healthcare Conference, leading to profit-taking or a "sell the news" reaction.
• There might have been concerns raised during the presentation about the timeline for bringing their gene editing technology to market, causing uncertainty among investors.
• It's possible that some investors were expecting more concrete updates on the progress of their Prime Editing platform or the results of ongoing clinical trials, leading to disappointment and a sell-off in the stock.